SCHEDULE 13G/A: Alger Associates Discloses 5.1% Passive Stake in Cryoport, Inc.

Alger Associates, Inc. has filed an amended Schedule 13G, reporting a 5.1% passive beneficial ownership stake in Cryoport, Inc. as of March 31, 2025.

Summary

• Alger Associates, Inc. reported beneficial ownership of 2,532,362 shares of Cryoport, Inc. Common Stock.
• This represents 5.1% of Cryoport, Inc.'s outstanding common stock.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating a previous filing by Alger Associates, Inc.
• Alger Associates, Inc. holds sole voting power and sole dispositive power over all 2,532,362 reported shares.
• The securities are beneficially owned by investment management clients of Fred Alger Management, LLC (FAM), a registered investment adviser and a 100% owned subsidiary of Alger Group Holdings, LLC (AGH), which is a 100% owned subsidiary of Alger Associates, Inc.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Cryoport, Inc.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. It's a routine disclosure of a significant passive stake, which is generally a positive sign of institutional confidence, but provides no new operational or financial news about Cryoport, Inc. itself.

Positives

• A significant institutional investor, Alger Associates, Inc., maintains a substantial passive stake in Cryoport, Inc., indicating continued confidence in the company.
• The filing confirms the investment is for ordinary course of business, not for control, which suggests stability in the shareholder base and no immediate activist intentions.

Future Outlook

This Schedule 13G filing does not provide forward-looking statements or guidance regarding Cryoport, Inc.'s future performance or operations, as it is solely a disclosure of beneficial ownership by an institutional investor.

Management Comments

• The filing includes a certification from Alger Associates, Inc. stating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Cryoport, Inc.

Industry Context

This filing reflects an institutional investor's continued stake in Cryoport, Inc., a company operating in the life sciences and cold chain logistics sector. Such disclosures are routine for significant passive investments and do not inherently indicate a shift in broader industry trends, but rather an investor's specific allocation within the sector.

Comparison to Industry Standards

• As a Schedule 13G filing, this document primarily reports beneficial ownership and does not contain financial or operational results that can be directly compared to industry standards or specific comparable companies/projects. It indicates a standard passive investment by an asset manager.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, potentially reinforcing confidence in the stock due to institutional backing.

Key Dates

Keywords

Cryoport Inc., Alger Associates Inc., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing, Investment Management